دورية أكاديمية

The efficacy and safety of a new reduced-toxicity conditioning with 4 days of once-daily 100 mg/m intravenous busulfan associated with fludarabine and antithymocyte globulins prior to allogeneic stem cell transplantation in patients with high-risk myelodysplastic syndrome or acute leukemia

التفاصيل البيبلوغرافية
العنوان: The efficacy and safety of a new reduced-toxicity conditioning with 4 days of once-daily 100 mg/m intravenous busulfan associated with fludarabine and antithymocyte globulins prior to allogeneic stem cell transplantation in patients with high-risk myelodysplastic syndrome or acute leukemia
المؤلفون: Wanquet, Anne, Crocchiolo, Roberto, Furst, Sabine, Granata, Angela, Faucher, Catherine, Devillier, Raynier, Harbi, Samia, Lemarie, Claude, Calmels, Boris, Vey, Norbert, Weiller, Pierre Jean, Chabannon, Christian, Castagna, Luca, Blaise, Didier, El-Cheikh, Jean
المصدر: Leukemia & Lymphoma; Oct2016, Vol. 57 Issue 10, p2315-2320, 6p
مصطلحات موضوعية: STEM cell transplantation, HOMOGRAFTS, BUSULFAN, PHYSICAL training & conditioning, TOXICITY testing, DRUG efficacy
مستخلص: The optimal intensity of myeloablation associated with a reduced-toxicity conditioning (RTC) regimen in order to decrease the relapse rate without increasing non-relapse mortality (NRM), is not well established yet. This retrospective analysis was done on 30 patients with hematological malignancies. The aim was to assess the safety of a RTC regimen based on the busulfan at a dose of 100 mg/m2/d intravenously for 4 d, fludarabine at a dose of 30 mg/m2/d for 5 d, and anti-thymoglobulins at a dose of 2.5 mg/kg/d for 2 d. The cumulative incidences of grade 2–4 acute graft-versus-host disease (GVHD) and all grades chronic GVHD were 37% and 42%, respectively. Median 1-year overall survival and disease-free survival were 66% and 50%, respectively. At 1 year, the cumulative incidence of relapse/disease progression was 33%. NRM was 3% and 17% at day 100 and 1 year, respectively. This RTC conditioning regimen can lead to a long-term disease control. Moreover, it appears to be safe with a low NRM rate among high-risk patients. [ABSTRACT FROM AUTHOR]
Copyright of Leukemia & Lymphoma is the property of Taylor & Francis Ltd and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
قاعدة البيانات: Complementary Index
الوصف
تدمد:10428194
DOI:10.3109/10428194.2016.1146948